An Expert Report on Nicotinamide Riboside (DB14933)

1.0 Executive Summary

Nicotinamide riboside (NR) is a pyridine-nucleoside form of vitamin B3 that has emerged as a subject of intense scientific and public interest due to its role as a potent and orally bioavailable precursor to nicotinamide adenine dinucleotide (NAD+).[1]

NAD+ is an indispensable coenzyme central to cellular metabolism, energy production, and the regulation of critical signaling pathways that govern cellular health and longevity. The core mechanism of NR involves its efficient conversion to NAD+ via a unique two-step enzymatic pathway mediated by nicotinamide riboside kinases (NRKs), which bypasses rate-limiting steps in other biosynthetic routes.[1]

By elevating the cellular pool of NAD+, NR provides the necessary substrate for key NAD+-consuming enzymes, most notably the sirtuin (SIRT) family of protein deacetylases and poly(ADP-ribose) polymerases (PARPs). These enzymes are integral to processes such as DNA repair, mitochondrial biogenesis, inflammation modulation, and cellular stress responses.[2] As endogenous

NAD+ levels are known to decline with age, this decline has been implicated in the pathophysiology of numerous age-related conditions, positioning NR as a promising agent for healthy aging interventions.[2]

Clinical investigations have established a strong safety profile for NR, with human studies demonstrating its tolerability at doses up to 2,000-3,000 mg per day with few and mild side effects.[6] Research has explored its therapeutic potential across several domains, yielding promising results in neurodegenerative disorders, as exemplified by the NADPARK study in Parkinson's disease, which showed increased cerebral

NAD+ levels and mild clinical improvement.[8] Evidence also suggests benefits for cardiovascular health, including the potential to lower systolic blood pressure in at-risk populations.[9]

Reflecting its robust safety data, NR has achieved widespread regulatory acceptance as a dietary supplement and novel food ingredient from major international bodies, including the United States Food and Drug Administration (FDA), the European Food Safety Authority (EFSA), and the Australian Therapeutic Goods Administration (TGA), often marketed under the brand name Niagen®.[10]

In conclusion, nicotinamide riboside represents a well-validated and safe method for increasing systemic NAD+ levels in humans. While its foundational mechanism is well-understood, the translation of this biochemical effect into consistent and robust clinical benefits across its many potential applications remains an area of active and nuanced investigation. The existing evidence is promising, particularly for conditions characterized by metabolic stress and inflammation, but further large-scale clinical trials are required to definitively establish its therapeutic efficacy.

2.0 Compound Profile: Identification and Physicochemical Properties

A comprehensive understanding of nicotinamide riboside begins with its precise chemical identity, molecular structure, and key physicochemical characteristics, which collectively dictate its stability, formulation, and biological activity.

2.1 Nomenclature and Chemical Identifiers

Nicotinamide riboside is a small molecule that is systematically identified across various chemical and biological databases.

• Common Names: Nicotinamide riboside (NR), N-Ribosylnicotinamide, SR647.[1]
• Systematic IUPAC Name: 3-Carbamoyl-1-pyridin-1-ium.[1]
• Synonyms: 1-(β-D-Ribofuranosyl)nicotinamide, Nicotinamide Ribose, Nicotiamide Riboside, nicotinamide-beta-riboside.[1]
• Database Identifiers:
• DrugBank ID: DB14933
• CAS Number: 1341-23-7 (for the cation).[1] The commonly used chloride salt has a distinct CAS number of 23111-00-4.[16]
• PubChem CID: 439924.[1]
• ChEBI: CHEBI:15927.[1]
• UNII: 0I8H2M0L7N.[1]

2.2 Molecular Structure and Composition

The molecular formula and weight of NR vary depending on whether the free cation or a salt form is being described. This distinction is critical for accurate dosage calculations and interpretation of scientific literature.

• Molecular Formula: The active cation has a formula of C11​H15​N2​O5+​.[14] The commonly commercialized chloride salt has the formula C11​H15​ClN2​O5​.[16]
• Molecular Weight: The molecular weight of the free NR cation is 255.25 g/mol.[1] The chloride salt has a molecular weight of 290.70 g/mol, while another research-grade form, the triflate salt, is 404.31 g/mol.[1] This mass difference is significant; for instance, 100 mg of nicotinamide riboside chloride provides only 88 mg of the active NR cation.[1] A lack of precise reporting on the salt form used in studies or supplements can introduce a variance of approximately 12% in the actual dose of the active molecule, potentially confounding the comparison of results across different investigations. Therefore, it is essential for researchers and manufacturers to specify the exact form and calculate dosage based on the active cation's mass to ensure scientific rigor and reproducibility.
• Structural Identifiers:
• Canonical SMILES: C1=CC(=C[N+](=C1)C2C(C(C(O2)CO)O)O)C(=O)N.[14]
• InChIKey: JLEBZPBDRKPWTD-TURQNECASA-O.[13]

2.3 Physicochemical Characteristics and Stability Profile

NR is a relatively unstable molecule, and its physical properties have significant implications for its formulation, storage, and ultimate biological efficacy.

• Appearance: White to light brown powder or solid.[17]
• Solubility: It is highly soluble in aqueous solutions and polar organic solvents. The chloride salt has a reported solubility in water of ≥446.5 mg/mL and in DMSO of 50 mg/mL.[17]
• Melting Point: The melting point for the chloride salt is reported to be in the range of 115-125°C.[17] However, heating the compound to this temperature range is associated with significant degradation.
• Stability and Degradation: NR is a chemically labile molecule, characterized by a glycosidic bond joining a positively charged pyridinium ring to a ribose sugar.[21] This structure is susceptible to degradation under several conditions:
• Thermal Instability: The compound undergoes rapid decomposition at temperatures above 130°C, breaking down into its constituent parts: nicotinamide (NAM) and ribose. This degradation follows pseudo-first-order kinetics, with the rate doubling for every 10°C increase in temperature.[1]
• pH and Gastric Instability: NR is also susceptible to hydrolysis in solution, a process that is accelerated in acidic environments such as simulated gastric fluid. This degradation pathway also yields NAM.[22]
• Storage: To maintain integrity, NR should be stored at low temperatures, typically -20°C for long-term stability (≥4 years) or 2-8°C in an inert atmosphere for shorter periods.[13]

The physicochemical instability of NR is a critical factor influencing its biological effect. The primary degradation product, NAM, has a distinct pharmacological profile. While NR boosts NAD+ to activate sirtuin enzymes, high concentrations of NAM are known to act as an inhibitor of sirtuins.[25] This creates a scenario where improper manufacturing, storage at elevated temperatures, or formulation in a simple, non-protective capsule can lead to the in-situ generation of an antagonist (NAM) that directly counteracts the intended therapeutic mechanism of the parent compound (NR). This highlights the necessity for developing more stable forms, such as the reported NR borate [21], or employing advanced delivery systems like enteric coatings to protect the molecule from gastric degradation and maximize its bioavailability and efficacy.

Table 1: Physicochemical Properties of Nicotinamide Riboside

Parameter	Value (NR Cation)	Value (NR Chloride)	Source(s)
Systematic IUPAC Name	3-Carbamoyl-1-pyridin-1-ium	3-(Aminocarbonyl)-1-β-D-ribofuranosylpyridinium chloride	1
CAS Number	1341-23-7	23111-00-4	1
Molecular Formula	C11​H15​N2​O5+​	C11​H15​ClN2​O5​	14
Molecular Weight	255.25 g/mol	290.70 g/mol	1
Appearance	Solid	White to light brown powder	17
Melting Point	Not applicable	115-125°C (with degradation)	17
Solubility (Water)	High	≥446.5 mg/mL	17
Storage Conditions	-20°C (long-term)	-20°C (long-term)	13
Key Stability Notes	Labile; degrades to NAM + ribose with heat and in acidic conditions.	Labile; degrades to NAM + ribose with heat and in acidic conditions.	1

3.0 Mechanism of Action and Cellular Pharmacology

The pharmacological effects of nicotinamide riboside are mediated entirely through its role as a precursor to NAD+. Therefore, understanding NR's mechanism requires a foundational knowledge of the central role NAD+ plays in cellular physiology and how NR efficiently replenishes this critical coenzyme pool.

3.1 The Central Role of NAD+ in Cellular Metabolism and Signaling

Nicotinamide Adenine Dinucleotide (NAD+) is a ubiquitous coenzyme essential for life, participating in hundreds of critical cellular processes.[26] It exists in two forms, an oxidized state (

NAD+) and a reduced state (NADH), and the balance between these two forms, known as the NAD+/NADH ratio, is a fundamental indicator of a cell's redox and metabolic status.[28]

Role in Redox Reactions and Energy Metabolism: The classical and most well-known function of the NAD+/NADH couple is as a hydride carrier in cellular redox reactions.[30]

NAD+ acts as an oxidizing agent, accepting electrons from metabolites during catabolic processes such as glycolysis, the citric acid cycle (TCA), and fatty acid β-oxidation. The resulting NADH then donates these electrons to the mitochondrial electron transport chain, driving the production of adenosine triphosphate (ATP) through oxidative phosphorylation.[21] This function is fundamental to converting food into cellular energy.[2]

Role as a Signaling Substrate: Beyond its bioenergetic role, NAD+ is also consumed as a substrate by several families of signaling enzymes. In these non-redox reactions, the NAD+ molecule is cleaved, giving rise to nicotinamide (NAM) and an ADP-ribose moiety.[21] The primary

NAD+-consuming enzyme families include:

• Sirtuins (SIRTs): A class of seven (SIRT1-7 in mammals) NAD+-dependent protein deacetylases and deacylases. Sirtuins regulate a vast array of cellular functions, including gene expression, DNA repair, mitochondrial function, inflammation, and metabolic homeostasis. Their activity is directly linked to cellular NAD+ availability, positioning them as critical metabolic sensors.[2]
• Poly(ADP-ribose) Polymerases (PARPs): Primarily involved in the DNA damage response. Upon detecting DNA strand breaks, PARPs (especially PARP1 and PARP2) consume large amounts of NAD+ to synthesize chains of poly(ADP-ribose) on target proteins, which recruits DNA repair machinery.[33]
• cADP-ribose Synthases (CD38/CD157): These ectoenzymes hydrolyze NAD+ to generate second messengers like cyclic ADP-ribose, which regulate intracellular calcium signaling and immune responses. CD38 is considered the primary consumer of NAD+ in mammals, and its expression significantly increases with age, contributing to the age-related decline in NAD+ levels.[5]

Age-Related Decline of NAD+: A key factor driving interest in NR is the well-documented phenomenon that cellular and tissue levels of NAD+ decline progressively with age.[2] This decline is attributed to both a reduction in biosynthetic capacity and, more significantly, an increase in consumption by enzymes like PARPs (due to accumulated DNA damage) and CD38. This depletion of the

NAD+ pool is causally linked to many hallmarks of aging and the pathogenesis of age-related diseases, including metabolic syndrome, neurodegeneration, and cardiovascular disease.[26]

3.2 Nicotinamide Riboside as an Efficient NAD+ Precursor: The NRK Pathway

Mammalian cells utilize several pathways to synthesize NAD+. These include the de novo pathway, which starts from the amino acid tryptophan, and salvage pathways that recycle vitamin B3 precursors like nicotinic acid (NA; the Preiss-Handler pathway) and nicotinamide (NAM).[1]

Nicotinamide riboside utilizes a distinct and highly efficient salvage pathway that was first identified in eukaryotes in 2004.[1] Once NR enters a cell, a process facilitated by equilibrative nucleoside transporters, it is rapidly phosphorylated by nicotinamide riboside kinase enzymes (NRK1 and NRK2) to form nicotinamide mononucleotide (NMN).[1] This NMN is then adenylated by NMN-adenylyltransferase (NMNAT) enzymes to produce

NAD+.[1] This two-step conversion (NR

→ NMN → NAD+) is particularly efficient because it bypasses the NAMPT enzyme, which is the rate-limiting step in the primary salvage pathway that utilizes NAM.[1] This allows for a more direct and rapid replenishment of the

NAD+ pool, making NR a superior precursor in many contexts.[5] The expression of the NRK enzymes is tissue-specific, with NRK1 being predominant in the liver and kidney, and NRK2 more highly expressed in muscle tissues, particularly under conditions of metabolic stress or cellular damage.[1]

3.3 Downstream Pharmacological Effects: Activation of Sirtuins and Regulation of NAD+-Consuming Enzymes

By increasing the intracellular concentration of NAD+, NR supplementation provides the necessary fuel for NAD+-dependent enzymes, leading to a cascade of downstream pharmacological effects.

• Pan-Sirtuin Activation: The primary mechanism through which NR is thought to exert its health benefits is by functioning as a pan-sirtuin activator.[34] By boosting the availability of their obligatory co-substrate, NAD+, NR enhances the activity of multiple sirtuin enzymes.
• SIRT1 and SIRT3: Studies consistently show that NR supplementation increases the activity of the nuclear/cytosolic SIRT1 and the mitochondrial SIRT3. This leads to the deacetylation of key regulatory proteins such as PGC-1α (a master regulator of mitochondrial biogenesis) and FOXO1 (involved in stress resistance). The consequences include enhanced oxidative metabolism, improved mitochondrial function, reduced inflammation, and protection against metabolic abnormalities, such as those induced by high-fat diets in preclinical models.[2]
• SIRT5: More recent research has also identified NR as a selective allosteric activator of SIRT5, a mitochondrial sirtuin with emerging roles in cardiac health.[38]
• Modulation of Cellular Pathways: The activation of sirtuins and replenishment of NAD+ influences several key cellular processes:
• Mitochondrial Biogenesis and Function: Through the activation of the SIRT1/PGC-1α axis, NR promotes the creation of new mitochondria and enhances their function, leading to more efficient energy production and endurance in animal models.[3]
• Inflammation and Oxidative Stress: NR has been shown to reduce the expression of pro-inflammatory cytokines like TNF-α and IL-6 and to modulate inflammatory signaling pathways such as the NLRP3 inflammasome and NF-κB.[8] By boosting NAD+ and activating sirtuins, it also helps protect cells against oxidative stress.[2]

The efficacy of NR is likely highest under conditions where the cellular system is already under stress and NAD+ pools are depleted. The very conditions NR is meant to treat—such as metabolic stress and cellular damage—are known to upregulate the expression of the NRK enzymes required for its utilization.[1] This suggests a responsive system where metabolic stress primes the cell to more effectively use NR to restore homeostasis. This reframes NR not as a universal performance enhancer, but as a targeted "homeostatic restorative agent," implying its greatest potential lies in populations with demonstrable metabolic stress or age-related

NAD+ deficiency.

Furthermore, the newly synthesized NAD+ is subject to a competitive "tug-of-war" among its various consumers. In a state of high DNA damage, PARPs may preferentially consume the replenished NAD+, leaving less available for sirtuin activation. Similarly, in aged individuals with high CD38 expression, a significant portion of the NAD+ boost could be rapidly hydrolyzed. This dynamic suggests that the ultimate therapeutic outcome of NR supplementation depends heavily on the underlying cellular state and opens the door for future therapeutic strategies involving combination therapies, such as NR paired with a CD38 inhibitor, to more effectively direct the replenished NAD+ toward desired pathways like sirtuin activation.

4.0 Human Pharmacokinetics and Bioavailability

The clinical potential of nicotinamide riboside is fundamentally dependent on its absorption, distribution, metabolism, and excretion (ADME) profile in humans, which has been the subject of several key clinical studies.

4.1 Absorption, Distribution, Metabolism, and Excretion (ADME) Profile

• Absorption and Bioavailability: Clinical studies have unequivocally demonstrated that NR is orally bioavailable in humans.[40] Oral supplementation results in efficient absorption from the gastrointestinal tract and leads to dose-dependent increases in whole blood NAD+ concentrations and related metabolites.[6] While oral administration is the standard route, intravenous (IV) administration is also being explored as a method to bypass potential gastrointestinal degradation and hepatic first-pass metabolism, which may lead to a more potent and rapid impact on systemic NAD+ levels.[10]
• Distribution: Following absorption, NR and its metabolites are distributed systemically. Increased levels of NAD+ have been documented not only in whole blood and peripheral blood mononuclear cells (PBMCs) but also in tissues such as skeletal muscle.[6] Importantly, evidence suggests that NR supplementation can also impact the central nervous system, with studies showing increased NAD+ in neuronal extracellular vesicles and cerebrospinal fluid, indicating that it or its metabolites can cross the blood-brain barrier.[14]
• Metabolism: The primary metabolic fate of NR is its conversion to NAD+ via the NRK pathway, as detailed previously. A pivotal and initially unexpected discovery from human pharmacokinetic studies was that NR supplementation leads to a dramatic and dose-dependent increase in nicotinic acid adenine dinucleotide (NAAD).[40] This finding is particularly significant because it established NAAD as a highly sensitive pharmacodynamic biomarker of effective NAD+ repletion. While NAD+ itself is an abundant metabolite, making its relative changes difficult to detect with high sensitivity (a low signal-to-noise ratio), the normally trace-level NAAD increases by orders of magnitude upon NR administration.[45] This provides a much more robust signal to confirm that an individual is responding to supplementation and allows for more accurate dose-finding assessments.
• Excretion: The body utilizes NR very efficiently. Studies show that minimal amounts of unmodified NR are excreted in the urine, indicating near-complete metabolic conversion.[6] Instead, downstream metabolites of the NAD+ salvage pathway, such as methyl nicotinamide (MeNAM) and N-methyl-2-pyridone-3/5-carboximide (Me2PY), are the primary forms found in urine following supplementation.[46]

4.2 Dose-Response Relationship and Impact on the Blood NAD+ Metabolome

The first human clinical trials established a clear dose-response relationship for NR supplementation.

• Dose-Dependent Increases: Single oral doses of 100 mg, 300 mg, and 1,000 mg of NR were shown to produce progressively larger increases in the blood NAD+ metabolome.[40]
• Magnitude and Time Course: A pilot study involving a single individual taking 1,000 mg daily for seven days showed a 2.7-fold increase in blood NAD+.[40] A subsequent study in eight healthy volunteers using a dose-escalation protocol up to 2,000 mg/day demonstrated an average 2-fold increase in blood NAD+ by day 9.[43] Longer-term supplementation (56 days) with 1,000 mg/day resulted in a sustained 142% increase in whole blood NAD+.[46]
• Pharmacokinetic Profile: While specific values for Cmax, Tmax, and half-life of NR itself are not consistently reported, the effect on the NAD+ pool appears to be gradual and sustained. One study noted a "surprisingly slow increase of NAD levels in the blood over several days, as well as a slow decrease," rather than a sharp peak and rapid decline.[49] This suggests that NR supplementation does not merely provide an acute, transient boost but rather works to fundamentally alter the homeostatic set-point of the entire NAD+ metabolome. This "slow and steady" profile supports the rationale for consistent, long-term daily supplementation to achieve and maintain a new, higher steady-state level of NAD+, implying that the full physiological benefits may only emerge after this new metabolic equilibrium is established over days to weeks.

4.3 Comparative Analysis with Niacin and Nicotinamide Mononucleotide (NMN)

• vs. Niacin (NA) and Nicotinamide (NAM): Preclinical head-to-head comparisons have shown that oral NR possesses superior pharmacokinetics for elevating hepatic NAD+ compared to both NA and NAM.[40] Clinically, NR holds significant advantages in tolerability. It does not cause the uncomfortable skin flushing associated with higher doses of niacin, nor does it inhibit sirtuin activity at high concentrations, a known issue with NAM.[25]
• vs. Nicotinamide Mononucleotide (NMN): NMN is the direct downstream product of NR phosphorylation in the NAD+ synthesis pathway. A prevailing scientific consensus, supported by the identification of the cell-surface ectoenzyme CD73 which can dephosphorylate NMN, suggests that orally administered NMN must first be converted to NR to be transported into the cell, after which it is re-phosphorylated back to NMN intracellularly.[21] This makes NR a more direct precursor for cellular uptake. While NMN is also under investigation as an NAD+ booster, NR currently has a more extensive body of human clinical data and a more established global regulatory and safety profile.[39]

5.0 Analysis of Clinical Evidence by Therapeutic Area

While preclinical data for nicotinamide riboside is robust across a wide range of models, human clinical evidence is more nuanced, with promising results in some areas and mixed or null findings in others. A structured analysis of the major clinical trials provides insight into its current therapeutic potential.

Table 2: Summary of Major Human Clinical Trials of Nicotinamide Riboside

Trial Identifier (Name)	Indication/Population	Study Design	Dosage and Duration	Primary Endpoint(s)	Key Findings & Safety Notes	Source(s)
NCT03816020 (NADPARK)	Parkinson's Disease (newly diagnosed, n=30)	Phase I, RCT, Double-blind	1,000 mg/day for 30 days	Safety, Cerebral NAD levels	Well-tolerated. Significantly increased cerebral NAD levels. Associated with altered brain metabolism, mild clinical improvement, and reduced inflammatory cytokines.	8
NCT03821623	Elevated Systolic Blood Pressure (SBP) (n=94)	Phase IIa, RCT, Double-blind	1,000 mg/day for 3 months	Change in casual SBP	Based on a pilot study showing a 9 mmHg SBP reduction in adults with baseline SBP ≥120 mmHg. Main trial is ongoing.	9
NCT03423342	Heart Failure with Reduced Ejection Fraction (HFrEF) (n=30)	Phase I/II, RCT	Up to 2,000 mg/day for 12 weeks	Safety and Tolerability	Safe and well-tolerated. Doubled whole blood NAD levels. Increased NAD correlated with improved mitochondrial respiration and reduced NLRP3 expression in PBMCs.	51
NCT06208527 (NADage)	Age-Related Frailty (n=100)	RCT, Double-blind	2,000 mg/day for 52 weeks	Gait speed	Ongoing trial to assess if NR can decelerate functional decline in the elderly frail population.	54
Werner Syndrome Trial	Werner Syndrome (premature aging)	RCT, Double-blind, Crossover	Not specified	Safety, NAD levels, clinical markers	Safe. Increased blood NAD. Improved arterial stiffness, reduced skin ulcer area, and slowed progression of kidney dysfunction.	55
NCT03743636 (NICE)	Peripheral Artery Disease (PAD) (n=90)	Phase III, RCT	1,000 mg/day (with/without resveratrol) for 6 months	6-minute walk distance	Ongoing trial to assess improvement in walking performance.	57
Dollerup et al., 2018	Obesity & Insulin Resistance	RCT, Double-blind	2,000 mg/day for 12 weeks	Insulin sensitivity	Safe, but did NOT improve insulin sensitivity, glucose metabolism, or mitochondrial function in obese, insulin-resistant men.	59

5.1 Cardiovascular and Metabolic Health

An emerging pattern in human trials suggests a potential dissociation between cardiovascular and metabolic outcomes. While NR shows promise for vascular health, its effects on core metabolic parameters like insulin sensitivity have been less consistent.

• Hypertension and Arterial Stiffness: A pilot study demonstrated that NR supplementation (1,000 mg/day for 6 weeks) significantly lowered systolic blood pressure by 9 mmHg and reduced arterial stiffness in middle-aged and older adults with above-normal baseline blood pressure.[2] These clinically meaningful findings prompted a larger, ongoing Phase II trial (NCT03821623) to confirm efficacy.[9]
• Heart Failure: In patients with stable HFrEF, NR (2,000 mg/day for 12 weeks) was found to be safe and effective at doubling blood NAD+ levels. This increase was correlated with improved mitochondrial respiration in immune cells and a reduction in the pro-inflammatory marker NLRP3, pointing to a potential anti-inflammatory mechanism of action in this population.[51]
• Peripheral Artery Disease (PAD): The large, ongoing NICE trial (NCT03743636) is evaluating whether NR, alone or with resveratrol, can improve walking performance in PAD patients.[57] A preliminary pilot study in this population showed positive trends toward improved endothelial function and cognitive performance.[61]
• Metabolic Disorders: In contrast to the positive cardiovascular signals, the evidence for metabolic benefits in humans is weaker. A 12-week randomized controlled trial in obese, insulin-resistant men found that 2,000 mg/day of NR, while safe, failed to improve insulin sensitivity, glucose metabolism, or skeletal muscle mitochondrial function.[59] This stands in contrast to strong preclinical data where NR effectively protects mice against high-fat diet-induced obesity and metabolic dysfunction.[15] This suggests that the mechanisms governing vascular health may be more sensitive to NAD+ repletion than the deeply entrenched pathology of insulin resistance in established human obesity.

5.2 Neuroprotection and Cognitive Function

The role of NAD+ in neuronal health has positioned NR as a promising candidate for neurodegenerative diseases, with a recurring theme being the modulation of neuro-inflammation.

• Parkinson's Disease (PD): The Phase I NADPARK study provided compelling early evidence. In newly diagnosed PD patients, 1,000 mg/day of NR for 30 days safely increased NAD+ levels in the brain, altered cerebral metabolism, and was associated with mild clinical improvement.[8] A key finding was the reduction of inflammatory cytokines in both serum and cerebrospinal fluid, suggesting that its neuroprotective effects may be mediated, at least in part, by dampening neuro-inflammation.[8]
• Alzheimer's Disease (AD) and Mild Cognitive Impairment (MCI): Preclinical work in mouse models of AD showed NR could reduce cognitive decline.[15] This has led to several human trials. An early trial investigated NR's effect on memory and brain blood flow in older adults with MCI (NCT03482167) [62], and a current study is assessing its impact on brain energy metabolism and oxidative stress in individuals with MCI or mild AD.[63]

5.3 Healthy Aging and Longevity

NR is most widely known and marketed as an anti-aging supplement, and several large-scale trials are underway to substantiate these claims.

• Age-Related Frailty: The NADage study (NCT06208527) is a landmark, year-long trial investigating whether 2,000 mg/day of NR can slow functional decline in 100 frail elderly individuals, using gait speed as the primary outcome.[54] This and other trials aim to determine if boosting NAD+ can improve muscle function, bone health, and overall physical performance in aging populations.[64]
• Werner Syndrome: Perhaps the most striking evidence for NR's anti-aging potential comes from a trial in patients with Werner syndrome, a rare genetic disorder of accelerated aging. In this population, NR supplementation not only boosted NAD+ but also led to tangible clinical benefits, including improved arterial stiffness, healing of chronic skin ulcers, and slowed progression of kidney dysfunction.[55] The broad, multi-system benefits observed suggest that targeting NAD+ depletion may be a fundamental mechanism to counteract the aging process.

The consistent anti-inflammatory effects observed across diverse conditions—from neurodegeneration in PD to systemic inflammation in HFrEF—suggest that this is a core, pleiotropic mechanism of action for NR. Restoring NAD+ homeostasis appears to recalibrate the immune system, dampening the chronic, low-grade inflammation ("inflammaging") that is a common driver of pathology in many age-related diseases. This broadens NR's potential application from specific diseases to conditions characterized by chronic inflammation.

6.0 Safety, Tolerability, and Risk Assessment

A substantial body of evidence from human clinical trials has established a strong safety profile for nicotinamide riboside, which underpins its widespread availability as a dietary supplement.

6.1 Adverse Event Profile from Clinical Trials

Across numerous studies, NR has been consistently reported as safe and well-tolerated.[6]

• General Tolerability: High doses, including 1,000 mg/day, 2,000 mg/day, and up to 3,000 mg/day in a trial for Parkinson's disease, have been administered for weeks to months without inducing serious adverse events.[2]
• Reported Side Effects: When adverse events are reported, they are typically mild to moderate in nature. The most common side effects include gastrointestinal complaints such as nausea, stomach discomfort, and diarrhea, as well as fatigue and headaches.[2]
• Lack of Flushing: A significant advantage of NR over the traditional vitamin B3 form, niacin, is the absence of the characteristic and often uncomfortable skin flushing reaction, even at high doses. This greatly improves tolerability and patient compliance.[6]

6.2 Potential Drug Interactions and Contraindications

While generally safe, there are theoretical and observed interactions that warrant caution.

• Antihypertensive Drugs: NR has been shown to have a modest blood pressure-lowering effect. Therefore, co-administration with other antihypertensive medications could potentially lead to hypotension. Individuals on such medications should monitor their blood pressure closely when initiating NR supplementation.[59]
• Blood Sugar-Lowering Medications: As NAD+ metabolism is intricately linked to glucose homeostasis, there is a theoretical potential for interaction with anti-diabetic drugs like metformin or insulin. Caution is advised.[66]
• Cancer Treatments: The role of NAD+ in cancer is complex. While some processes might be inhibited, boosting NAD+ could theoretically fuel the growth of certain cancer cells or interfere with the mechanism of some chemotherapeutic agents. It is generally recommended to avoid NAD+ precursors during active cancer treatment unless advised by an oncologist.[66]
• Contraindications: The primary contraindication is a known hypersensitivity to the compound. It is generally advised that pregnant and lactating women avoid supplementation due to a lack of extensive data, although the European Food Safety Authority has established a safe intake level of 230 mg/day for this population.[67]

6.3 Dosage, Administration, and Regulatory Guidance

Dosage in clinical trials has varied widely based on the therapeutic goal, but regulatory bodies have provided guidance for general use.

• Recommended Dosages: Commercially available supplements typically recommend daily doses in the range of 250–300 mg.[2] Clinical trials have safely tested doses from 100 mg to 3,000 mg per day.[7] A common approach is to start with 100–300 mg/day for general wellness, with higher doses reserved for specific therapeutic investigations under medical supervision.[69]
• Administration: NR is administered orally in capsule or tablet form and can be taken with or without food.[2]
• Regulatory Status: NR has achieved robust regulatory acceptance globally, primarily based on its strong safety profile. This acceptance has preceded definitive proof of efficacy for specific diseases, creating a market dynamic where NR is positioned as a safe supplement rather than a targeted therapeutic.

Table 3: Global Regulatory Status and Recommended Intake Levels

Regulatory Body	Jurisdiction	Status/Designation	Recommended/Approved Daily Intake	Source(s)
U.S. Food and Drug Administration (FDA)	United States	Generally Recognized As Safe (GRAS); New Dietary Ingredient (NDI)	Up to 300 mg/day	10
European Food Safety Authority (EFSA)	European Union	Novel Food Ingredient	Up to 300 mg/day (adults); 230 mg/day (pregnant/lactating women)	67
Therapeutic Goods Administration (TGA)	Australia	Permissible ingredient in Complementary Medicines; Listed on ARTG	Not specified, follows product listing	11
Health Canada	Canada	Natural Health Product (NHP)	Varies by license; up to 900 mg/day approved for some products	11

7.0 Synthesis, Commercialization, and Future Outlook

The journey of nicotinamide riboside from a trace nutrient to a widely available supplement has been driven by advances in chemical synthesis and a growing body of research, though significant challenges and future opportunities remain.

7.1 Manufacturing Considerations and Compound Stability

While NR is found in trace amounts in natural sources like milk and yeast, the quantities are far too low for commercial extraction.[21] Consequently, all commercially available NR is produced via chemical synthesis.[17] The development of scalable synthesis methods has been crucial for enabling the large-scale clinical trials and consumer products available today.[21] However, a central challenge in manufacturing is the inherent chemical instability of the NR molecule. As previously noted, NR is susceptible to degradation from heat and acidic conditions, which can occur during production, transport, or storage.[21] This lability poses a significant risk to product quality and consistency, as degradation to nicotinamide (NAM) can compromise the intended mechanism of action. This underscores the critical need for stringent quality control in manufacturing and the development of more stable formulations. Innovations in this area, such as the exploration of more stable salt forms like NR borate, represent a key direction for improving the reliability and efficacy of NR products.[21]

7.2 Market Landscape and Commercial Formulations

Nicotinamide riboside is primarily marketed directly to consumers as an anti-aging and cellular health dietary supplement.[2]

• Key Commercial Product: The market is dominated by Niagen®, the patented form of nicotinamide riboside chloride developed by ChromaDex. This is the form of NR that has been used in the majority of human clinical trials and is the subject of the key GRAS, NDI, and Novel Food regulatory filings worldwide.[2]
• Combination Products: To capitalize on synergistic mechanisms, some manufacturers offer formulations that combine NR with other bioactive compounds. A common combination is NR with pterostilbene, a polyphenol structurally similar to resveratrol, with the hypothesis that pterostilbene can further activate the SIRT1 enzyme, amplifying the effects of the NR-driven NAD+ boost.[2]

7.3 Critical Analysis of Research Gaps and Future Directions

Despite significant progress, several critical questions must be addressed to fully realize the therapeutic potential of NR.

• The Translational Gap: The most significant research gap is the discrepancy between the consistent and robust ability of NR to increase NAD+ levels and the often inconsistent or modest clinical outcomes observed in human trials, particularly in metabolic disease. Future research must elucidate the factors that govern this translational gap—whether they are related to dosage, duration, population selection, or the complex, competitive dynamics of the intracellular NAD+ metabolome.
• Optimizing Treatment Paradigms: It remains unclear who is most likely to benefit from NR supplementation. Future studies should focus on identifying the optimal dose and duration of treatment for specific conditions and should prioritize populations with a clear biological rationale for NAD+ depletion, where the potential for benefit is highest.
• Biomarker Development: The discovery of NAAD as a sensitive pharmacodynamic biomarker was a major advance.[40] Further validation of NAAD and the identification of additional biomarkers that can predict clinical response will be crucial for personalizing therapy and designing more efficient clinical trials.
• Combination Therapies: A promising future direction lies in the exploration of combination therapies. Pairing NR with agents that inhibit major NAD+ consumers (like CD38 inhibitors) could be a powerful strategy to maximize the increase in NAD+ and preferentially channel it towards beneficial pathways, such as sirtuin activation.
• Long-Term Safety and Efficacy: While short- and medium-term safety is well-established, data on the effects and safety of chronic, multi-year or even decade-long supplementation is needed to fully assess its role in long-term health and longevity.[2]

8.0 Comprehensive Conclusion and Expert Recommendations

Nicotinamide riboside has been firmly established as a safe, orally bioavailable, and effective precursor for increasing the systemic pool of the vital coenzyme NAD+ in humans. Its mechanism of action, centered on replenishing age-related or stress-induced declines in NAD+ to fuel essential cellular processes like DNA repair and sirtuin-mediated signaling, is supported by a strong foundation of preclinical and mechanistic research. This, combined with an excellent safety profile and broad global regulatory acceptance, has rightfully positioned NR as a leading compound in the field of healthy aging and metabolic research.

However, a critical evaluation of the current clinical evidence reveals a landscape of promise tempered by nuance. While NR consistently elevates its biochemical target (NAD+), the translation of this effect into definitive clinical benefits is not yet universal. The most compelling evidence for efficacy has emerged in specific contexts: as a potential neuroprotective and anti-inflammatory agent in Parkinson's disease, as a modulator of vascular health with the potential to lower blood pressure, and as a multi-system therapeutic in the rare premature aging disorder, Werner syndrome. In contrast, its utility for common metabolic disorders like obesity and insulin resistance in humans remains unproven, highlighting a significant gap with preclinical findings.

Based on this comprehensive analysis, the following recommendations are proposed to guide the future development and application of nicotinamide riboside.

8.1 Recommendations for Future Clinical Investigation and Potential Therapeutic Positioning

• Recommendation 1 (Trial Design): Future clinical trials must evolve beyond demonstrating an increase in NAD+ levels as a primary outcome. They require adequate statistical power, longer durations to capture chronic adaptations, and a focus on robust, clinically meaningful endpoints. The use of sensitive pharmacodynamic biomarkers, particularly NAAD, should be standard practice to confirm target engagement, stratify participants, and identify responders versus non-responders.
• Recommendation 2 (Target Population): To maximize the probability of success, research efforts should be prioritized for populations with a strong biological rationale for NAD+ deficiency. This includes the elderly frail, patients with diagnosed mitochondrial diseases, and individuals with conditions characterized by chronic inflammation. Investigating NR in young, healthy populations is less likely to yield significant benefits due to a probable ceiling effect on already replete NAD+ pools.
• Recommendation 3 (Formulation and Quality Control): Given the documented chemical instability of NR, it is imperative that all clinical research rigorously controls for and reports on the purity, stability, and formulation of the investigational product. Head-to-head trials comparing the bioavailability and efficacy of different salt forms (e.g., chloride vs. borate) and delivery systems (e.g., standard vs. enteric-coated capsules) are warranted to optimize clinical outcomes.
• Recommendation 4 (Therapeutic Positioning): Based on the current weight of evidence, the most promising near-term therapeutic applications for NR are as an adjunctive therapy for neurodegenerative diseases where neuro-inflammation is a key pathological driver, and as a potential intervention for managing endothelial dysfunction and elevated blood pressure. Its broader positioning as a general "anti-aging" supplement requires substantiation from large, long-term human studies focused on healthspan and functional outcomes.

Works cited

1. Nicotinamide riboside - Wikipedia, accessed September 28, 2025, https://en.wikipedia.org/wiki/Nicotinamide_riboside
2. Nicotinamide Riboside: Benefits, Side Effects and Dosage - Healthline, accessed September 28, 2025, https://www.healthline.com/nutrition/nicotinamide-riboside
3. The NAD+ precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet induced obesity - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3616313/
4. Cellular Repair and Reversal of Aging: the Role of NAD - CellR4, accessed September 28, 2025, https://www.cellr4.org/article/852
5. What is nicotinamide riboside? - Elysium Health, accessed September 28, 2025, https://www.elysiumhealth.com/blogs/aging101/what-is-nicotinamide-riboside
6. Pharmacokinetics and metabolism of nicotinamide riboside in humans - Consensus, accessed September 28, 2025, https://consensus.app/search/pharmacokinetics-and-metabolism-of-nicotinamide-ri/Yyg18pS4S1Cae7mm65Iiyw/
7. Long-term safety of nicotinamide riboside and mononucleotide supplementation, accessed September 28, 2025, https://consensus.app/search/long-term-safety-of-nicotinamide-riboside-and-mono/SOP0-qe1RMeN1lUCqGyMdQ/
8. The NADPARK study: A randomized phase I trial of nicotinamide ..., accessed September 28, 2025, https://pubmed.ncbi.nlm.nih.gov/35235774/
9. Nicotinamide Riboside Supplementation for Treating ... - Frontiers, accessed September 28, 2025, https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.881703/full
10. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV and NAD+ IV in healthy adults | medRxiv, accessed September 28, 2025, https://www.medrxiv.org/content/10.1101/2024.06.06.24308565v1.full
11. FDA GRAS no objection for Niagen (nicotinamide riboside chloride) on August 05, 2016, accessed September 28, 2025, https://pages.truniagen.com/regulatory/
12. ChromaDex Receives Approval for Nicotinamide Riboside Chloride as an Ingredient for Complementary Medicines from the Australian Therapeutic Goods Administration (TGA) - Niagen Bioscience - Investor Relations, accessed September 28, 2025, https://investors.chromadex.com/news/news-details/2019/ChromaDex-Receives-Approval-for-Nicotinamide-Riboside-Chloride-as-an-Ingredient-for-Complementary-Medicines-from-the-Australian-Therapeutic-Goods-Administration-TGA/default.aspx
13. Nicotinamide riboside | 1341-23-7 - Sigma-Aldrich, accessed September 28, 2025, https://www.sigmaaldrich.com/US/en/product/ambeedinc/ambh97f04517
14. CAS 1341-23-7 Nicotinamide riboside - Alfa Chemistry, accessed September 28, 2025, https://www.alfa-chemistry.com/nicotinamide-riboside-cas-1341-23-7-item-290045.htm
15. Nicotinamide riboside (CAS Number: 1341-23-7) | Cayman Chemical, accessed September 28, 2025, https://www.caymanchem.com/product/23132/nicotinamide-riboside
16. Nicotinamide Riboside | Other Kinases | Tocris Bioscience, accessed September 28, 2025, https://www.tocris.com/products/nicotinamide-riboside_6018
17. Nicotinamide riboside chloride | Therapeutic Goods Administration (TGA), accessed September 28, 2025, https://www.tga.gov.au/resources/resource/compositional-guidelines/nicotinamide-riboside-chloride
18. Nicotinamide Riboside Triflate | CAS# 1341-23-7 | NAD+ Precursor - MedKoo Biosciences, accessed September 28, 2025, https://www.medkoo.com/products/29532
19. Nicotinamide riboside - GlpBio, accessed September 28, 2025, https://www.glpbio.com/nicotinamide-riboside.html
20. T13795-5mg | Nicotinamide riboside [1341-23-7] Clinisciences, accessed September 28, 2025, https://www.clinisciences.com/en/other-products-186/nicotinamide-riboside-1341-23-7-24000802.html
21. Nicotinamide Riboside, a Promising Vitamin B3 Derivative for Healthy Aging and Longevity: Current Research and Perspectives - MDPI, accessed September 28, 2025, https://www.mdpi.com/1420-3049/28/16/6078
22. Understanding the physicochemical properties and degradation kinetics of nicotinamide riboside, a promising vitamin B - Food & Nutrition Research, accessed September 28, 2025, https://foodandnutritionresearch.net/index.php/fnr/article/view/3419/9477
23. (PDF) Understanding the physicochemical properties and degradation kinetics of nicotinamide riboside, a promising vitamin B 3 nutritional supplement - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/337486509_Understanding_the_physicochemical_properties_and_degradation_kinetics_of_nicotinamide_riboside_a_promising_vitamin_B_3_nutritional_supplement
24. Understanding the physicochemical properties and degradation kinetics of nicotinamide riboside, a promising vitamin B3nutritional supplement - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6878970/
25. What Are NAD+ Precursors? - AboutNAD, accessed September 28, 2025, https://www.aboutnad.com/pages/nad-precursors
26. NAD+ metabolism and its roles in cellular processes during ageing - PMC - PubMed Central, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
27. NAD+ Metabolism: Implications in Cellular Energy and Health - Creative Proteomics, accessed September 28, 2025, https://metabolomics.creative-proteomics.com/resource/nadh-metabolism-cellular-energy.htm
28. NAD+ Function In Cellular Metabolism - Consensus Academic Search Engine, accessed September 28, 2025, https://consensus.app/questions/nad-function-in-cellular-metabolism/
29. Decoding the NAD+/NADH Ratio and Its Crucial Role in Cell Health - Promega Connections, accessed September 28, 2025, https://www.promegaconnections.com/decoding-the-nad-nadh-ratio-and-its-crucial-role-in-cell-health/
30. Nicotinamide adenine dinucleotide - Wikipedia, accessed September 28, 2025, https://en.wikipedia.org/wiki/Nicotinamide_adenine_dinucleotide
31. The emergence of the nicotinamide riboside kinases in the regulation of NAD+ metabolism - Journal of Molecular Endocrinology, accessed September 28, 2025, https://jme.bioscientifica.com/downloadpdf/journals/jme/61/3/JME-18-0085.pdf
32. Role of NAD+ in regulating cellular and metabolic signaling pathways - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7973386/
33. Nicotinamide Riboside—The Current State of Research and Therapeutic Uses - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7352172/
34. Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside - Frontiers, accessed September 28, 2025, https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2021.755060/full
35. pmc.ncbi.nlm.nih.gov, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9194868/#:~:text=Of%20note%2C%20NAD%2B%20serves%20as,damage%20repair%2C%20and%20gene%20expression.
36. Fueling genome maintenance: On the versatile roles of NAD+ in preserving DNA integrity - PMC - PubMed Central, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9194868/
37. Nicotinamide riboside – Knowledge and References - Taylor & Francis, accessed September 28, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Nicotinamide_riboside/
38. Nicotinamide riboside activates SIRT5 deacetylation - PubMed, accessed September 28, 2025, https://pubmed.ncbi.nlm.nih.gov/37289138/
39. Nicotinamide Riboside Benefits and Anti-Aging Properties - Verywell Health, accessed September 28, 2025, https://www.verywellhealth.com/the-benefits-of-nicotinamide-riboside-7866970
40. Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, accessed September 28, 2025, https://iro.uiowa.edu/esploro/outputs/journalArticle/Nicotinamide-riboside-is-uniquely-and-orally/9983788598902771
41. Nicotinamide riboside is uniquely and orally bioavailable in mice ..., accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5062546/
42. (PDF) Nicotinamide riboside is uniquely and orally bioavailable in mice and humans, accessed September 28, 2025, https://www.researchgate.net/publication/308999969_Nicotinamide_riboside_is_uniquely_and_orally_bioavailable_in_mice_and_humans
43. Nicotinamide Riboside Supplementation Increases Blood NAD+ Levels in Healthy Humans: Clinical Findings - AboutNAD, accessed September 28, 2025, https://www.aboutnad.com/blogs/studies/an-open-label-non-randomized-study-of-the-pharmacokinetics-of-the-nutritional-supplement-nicotinamide-riboside-nr-and-its-effects-on-blood-nad-levels-in-healthy-volunteers
44. Ageing Recruiting Phase 2 Trials for Nicotinamide riboside (DB14933) | DrugBank Online, accessed September 28, 2025, https://go.drugbank.com/indications/DBCOND0032392/clinical_trials/DB14933?phase=2&status=recruiting
45. First human clinical trial for nicotinamide riboside | Carver College of Medicine, accessed September 28, 2025, https://medicine.uiowa.edu/news/2016/10/first-human-clinical-trial-nicotinamide-riboside
46. (PDF) Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/334256296_Safety_and_Metabolism_of_Long-term_Administration_of_NIAGEN_Nicotinamide_Riboside_Chloride_in_a_Randomized_Double-Blind_Placebo-controlled_Clinical_Trial_of_Healthy_Overweight_Adults
47. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers - PubMed Central, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5718430/
48. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults - PMC - PubMed Central, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6611812/
49. A pharmacokinetic study of NAD ... - Bergen Open Research Archive, accessed September 28, 2025, https://bora.uib.no/bora-xmlui/handle/11250/3071695?show=full
50. Niacin, NR, or NMN? The Best NAD+ Boosters Compared - MitoQ, accessed September 28, 2025, https://www.mitoq.com/blogs/journal/niacin-vs-nr-vs-nmn-which-nad-booster-works-best
51. Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction - PMC, accessed September 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9831861/
52. Safety and Tolerability of Nicotinamide Riboside in Heart Failure ..., accessed September 28, 2025, https://www.jacc.org/doi/abs/10.1016/j.jacbts.2022.06.012
53. Study Details | NCT03423342 | Nicotinamide Riboside in Systolic Heart Failure, accessed September 28, 2025, https://clinicaltrials.gov/study/NCT03423342
54. NCT06208527 | The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging | ClinicalTrials.gov, accessed September 28, 2025, https://clinicaltrials.gov/study/NCT06208527
55. Common supplement reverses premature aging in landmark human ..., accessed September 28, 2025, https://www.sciencedaily.com/releases/2025/06/250609020625.htm
56. Vitamin B3 Pill Rewinds Premature Aging in Groundbreaking Human Trial - SciTechDaily, accessed September 28, 2025, https://scitechdaily.com/vitamin-b3-pill-rewinds-premature-aging-in-groundbreaking-human-trial/
57. Study Details | NCT03743636 | Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease | ClinicalTrials.gov, accessed September 28, 2025, https://clinicaltrials.gov/study/NCT03743636
58. Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease | Clinical Research Trial Listing - CenterWatch, accessed September 28, 2025, https://www.centerwatch.com/clinical-trials/listings/NCT03743636/nicotinamide-riboside-with-and-without-resveratrol-to-improve-functioning-in-peripheral-artery-disease
59. NICOTINAMIDE RIBOSIDE: Overview, Uses, Side Effects, Precautions, Interactions, Dosing and Reviews - WebMD, accessed September 28, 2025, https://www.webmd.com/vitamins/ai/ingredientmono-1560/nicotinamide-riboside
60. Nicotinamide Riboside Clinical Trials - Consensus Academic Search Engine, accessed September 28, 2025, https://consensus.app/questions/nicotinamide-riboside-clinical-trials/
61. Effects of NAD+ Supplementation with Oral Nicotinamide Riboside (NR) on Vascular Health and Cognitive Function in Older Adults with Peripheral Artery Disease: Results from a Pilot 4-Week Open-Label Clinical Trial - ResearchGate, accessed September 28, 2025, https://www.researchgate.net/publication/391763337_Effects_of_NAD_Supplementation_with_Oral_Nicotinamide_Riboside_NR_on_Vascular_Health_and_Cognitive_Function_in_Older_Adults_with_Peripheral_Artery_Disease_Results_from_a_Pilot_4-Week_Open-Label_Clinic
62. Nicotinamide riboside Completed Phase 1 Trials for Mild Cognitive Impairment (MCI) Treatment | DrugBank Online, accessed September 28, 2025, https://go.drugbank.com/drugs/DB14933/clinical_trials?conditions=DBCOND0038137&phase=1&purpose=treatment&status=completed
63. Nicotinamide Riboside Supplement for Mild Cognitive Impairment and Mild Alzheimer's, accessed September 28, 2025, https://www.alzheimers.gov/clinical-trials/nicotinamide-riboside-supplement-mild-cognitive-impairment-and-mild-alzheimers
64. Current and Ongoing Clinical Trials | Elysium Health, accessed September 28, 2025, https://www.elysiumhealth.com/blogs/clinical-trials
65. Nicotinamide Riboside Side Effects - Consensus Academic Search Engine, accessed September 28, 2025, https://consensus.app/questions/nicotinamide-riboside-side-effects/
66. 7 Medications and Supplements Not To Mix With NAD+ - Health, accessed September 28, 2025, https://www.health.com/medications-not-to-mix-with-nad-11685772
67. Safety of nicotinamide riboside chloride as a novel food pursuant to Regulation (EU) 2015/2283 and bioavailability of nicotinamide from this source, in the context of Directive 2002/46/EC | EFSA - European Union, accessed September 28, 2025, https://www.efsa.europa.eu/en/efsajournal/pub/5775
68. REGULATIONS - EUR-Lex - European Union, accessed September 28, 2025, https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32020R0016
69. Understanding Nicotinamide Riboside Dosage - What You Need To Know - Drip Hydration, accessed September 28, 2025, https://driphydration.com/blog/nicotinamide-riboside-dosage/
70. NAD+ Supplementation: Navigating Dosage And Safety - Advanced Wellness And Pain, accessed September 28, 2025, https://advancedwellnessandpain.com/nad-supplementation-navigating-dosage-and-safety/
71. Nicotinamide Riboside NR (419551) - Therapeutic Goods Administration (TGA), accessed September 28, 2025, https://www.tga.gov.au/resources/artg/419551